Cargando…
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063497/ https://www.ncbi.nlm.nih.gov/pubmed/27785448 http://dx.doi.org/10.2147/OV.S99532 |